How can we select the best targeted agent(s) for patients with CLL?

During the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), the Lymphoma Hub spoke with Richard Rosenquist, Karolinska Institutet, Stockholm, SE. We asked, How can we select the best targeted agent(s) for patients with chronic lymphocytic leukemia (CLL)?

Rosenquist begins by highlighting that we are in the precision medicine era and explains diagnostic markers and their prognostic impacts such as TP53 mutations. He goes on to discuss IDH1 mutations as a strong prognostic and predictive marker, especially for targeted therapies such as BTK inhibitors and BCL2 inhibitors. Finally, he discusses complex karyotypes where studies have found that five or more aberrations were linked to poor outcomes.